Skip to content
CancerIndex

Publication

CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.

Ibrahim Aldoss, Lior Goldberg, Jianying Zhang, Andrew Artz, Mary C Clark, Min Guan, Ruby Espinosa, Thiruvaimozhi Abimannan, Jiaqi Wu, Bryan Garcia, Eric R Haas, Khyatiben V Pathak, Brooke Lovell, Patrick Pirrotte, Vaibhav Agrawal, Neguine Sanani, Stephanie Kasten, Dileshni Tilakawardane, Jamie R Wagner, Jinny Paul, Haoyue Shan, Samer Khaled, Lihua E Budde, Paul Koller, Anthony S Stein, Vinod Pullarkat, Amandeep Salhotra, Ahmed Aribi, Guido Marcucci, Xiuli Wang, Stephen J Forman

Blood advancesSep 8, 2026PMID 42341322doi:10.1182/bloodadvances.2026020963 PMC13544187Journal ArticleClinical Trial, Phase IpubmedProvenance
Source
PubMed
Retrieved
Sep 19, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260919-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

We report a phase 1 study assessing the safety and efficacy of CD19 chimeric antigen receptor (CAR) T cells as definitive consolidation in older adults (aged ≥55 years) with B-cell acute lymphoblastic leukemia (B-ALL) in first complete remission (CR1). Eighteen patients received lymphodepletion…

Read on PubMed

Linked entities

Linked entities (2)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 2

Registered trialsNCT02146924NCT05707273

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.